Anti-MuSK antibody Myasthenia gravis: Clinical findings and response to treatment in two large cohorts

Muscle and Nerve

Volumn 44, Issue 1, 2011, Pages 36-40

  Guptill, Jeffrey T ^a   Sanders, Donald B ^a   Evoli, Amelia ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Autoantibodies; Immunosuppression; Muscle specific kinase; MuSK; Myasthenia gravis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; EDROPHONIUM; HYDROCODONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MAGNESIUM; MUSCLE SPECIFIC TYROSINE KINASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PHOSPHOTRANSFERASE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ARTICLE; BULBAR PARALYSIS; CORTICOSTEROID THERAPY; DIPLOPIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; ELECTRODIAGNOSIS; EXTRAOCULAR MUSCLE; FACE MUSCLE; FACE WEAKNESS; FASICULATION; FEMALE; FOLLOW UP; GENERALIZED WEAKNESS; HISTOPATHOLOGY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; LIMB WEAKNESS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL MYOPATHY; MONOTHERAPY; MUSCLE CRAMP; MUSCLE TWITCH; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NECK WEAKNESS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PTOSIS; RESPIRATORY FAILURE; SIDE EFFECT; SYMPTOM; THYMECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE; WEAKNESS; WORSENING SYMPTOM;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CHILD; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PLASMA EXCHANGE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959324658     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22006     Document Type: Article

References (20)

1. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
2. Evoli A, Tonali PA, Padua L, Lo Monaco M, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-2311.
3. Sanders DB, el-Salem K, Massey JM, Vincent A. Muscle specific tyrosine kinase (MuSK) positive, seronegative myasthenia gravis. Clinical characteristics and response to therapy. Neurology 2003;60(supp l1): A418.
4. Lavrnic D, Losen M, de Baets M, Hajdukovic LJ, Stojanovic V, Trikic R, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005;76:1099-1102.
5. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Özdemir C, et al. Clinical comparison of anti-MuSK- vs anti-AChRpositive and seronegative myasthenia gravis. Neurology 2007;68:609-611.
6. Niks EH, Kuks JBM, Wokke JHJ, Veldman H, Bakker E, Verschuuren JJGM, et al. Pre- and postsynaptic neuromuscular junction abnormalities in MuSK myasthenia. Muscle Nerve 2010;42:283-288.
7. Cole RN, Reddel SW, Gervásio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008;63:782-789.
8. Cole RN, Ghazanfari N, Ngo ST, Gervásio OL, Reddel SW, Phillips WD. Patient autoantibodies deplete postsynaptic muscle specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 2010;588:3217-3229.
9. Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, Jie C, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006;116:1016-1024.
10. Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005;18:519-525.
11. Pasnoor M, Wolfe GI, Nations S, Trivedi J, Barohn RJ, Herbelin L, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010;41:370-374.
12. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann NY Acad Sci 2003;998:440-444.
13. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis. Recommendations for clinical research standards. Neurology 2000;55:16-23.
14. Sanders DB. Approach to diseases of the neuromuscular junction. In: Tawil R, Venance S, editors. Neurology in practice (in press).
15. Sanders DB, El Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980.
16. Hatanaka Y, Hemmi S, Morgan MB, Scheufele GC, Claussen GC, Wolfe GI, et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 2005;65:1508-1509.
17. Guptill JT, Sanders DB. Update on MuSK antibody positive myasthenia gravis. Curr Opin Neurol 2010;23:530-535.
18. Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 2005;116:2065-2068.
19. Oh SJ, Morgan MB, Lu L, Hatanaka Y, Hemmi S, Young A, et al. Racial differences in myasthenia gravis in Alabama. Muscle Nerve 2009;39:328-332.
20. Suhail H, Subbiah V, Singh S, Behari M. Musk-antibody positive myasthenia gravis and their clinical features in North India. Neurology 2010;74(suppl 2):A91-A92.